MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...

added 4.64% or 1.37 points to end at 30.76 and Deutsche Telekom AG Na (ETR:DTEGn) was up 3.30% or 0.92 points to 28.77 in ...

Germany equities were higher at the close on Thursday, as gains in the Technology, Telecoms and Media sectors propelled ...

The global urinary antibacterial and antiseptic pharmaceuticals market is projected to grow at a robust Compound Annual Growth Rate (CAGR) of 4.3% during the forecast period, driven by increasing ...

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

The annual inflation rate in Sweden stood at 1.6% in October. On the corporate front, major European companies, including ...

European markets are heading for a mixed open Thursday as traders assessed the global inflation outlook and the possible ...

Dr. Vink brings over 35 years of industry experience and currently serves as Chairman and Board member of several public and ...

United Therapeutics' pipeline and Tyvaso DPI drive strong growth. Read why UTHR stock offers substantial upside with ...

Visit www.neptune-software.com. Merck , known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, and Dr. Marjorie Green, ...